Patents Represented by Attorney, Agent or Law Firm Mark T. Kresnak
  • Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
    Patent number: 8008442
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: April 22, 2004
    Date of Patent: August 30, 2011
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Serpentine transmembrane antigens expressed in human cancers and uses thereof
    Patent number: 7968307
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: June 28, 2011
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
    Patent number: 7947276
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: May 24, 2011
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Serpentine transmembrane antigens expressed in human cancers and uses thereof
    Patent number: 7947459
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high'degree of structural conservation among them but show no significant structural homology to any known human proteins. STEAP-2 is a 454 amino acid protein characterized by a predicted molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Grant
    Filed: January 6, 2004
    Date of Patent: May 24, 2011
    Assignee: Agensys, Inc.
    Inventors: Rene S. Hubert, Arthur B. Raitano, Douglas Saffran, Daniel E. H. Afar, Steven Chappell Mitchell, Mary Faris, Aya Jakobovits
  • Reduction of cell-cell communication in prostate cancer using STEAP-1 siRNA
    Patent number: 7939503
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: May 10, 2011
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Serpentine transmembrane antigens expressed in human cancers and uses thereof
    Patent number: 7928201
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: April 19, 2011
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
    Patent number: 7884179
    Abstract: A novel gene 08P1D4 (also designated STEAP-1) and its encoded protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: February 8, 2011
    Assignee: Agensys, Inc.
    Inventors: Mary Faris, Wangmao Ge, Arthur B. Raitano, Pia M. Challita-Eid, Aya Jakobovits
  • Anti-PRO7168 antibodies
    Patent number: 7452975
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: November 18, 2008
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Dan L. Eaton, Ellen Filvaroff, Audrey Goddard, J. Christopher Grimaldi, Austin L. Gurney, Victoria Smith, Jean Philippe Stephan, Colin K. Watanabe, William I. Wood, Zemin Zhang, Sherman Fong
  • Method of inhibiting insulin-like growth factor-1 (IGF-1) by IGF-1-antagonist peptides
    Patent number: 7432244
    Abstract: Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: October 7, 2008
    Assignee: Genentech, Inc.
    Inventors: Kurt D. Deshayes, Henry B. Lowman, Michelle L. Schaffer, Sachdev S. Sidhu
  • Compositions and methods for the treatment of immune related diseases
    Patent number: 7419799
    Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: September 2, 2008
    Assignee: Genetech, Inc.
    Inventors: Patricia A. Valdez, Austin L. Gurney, Iqbal Grewal
  • Compositions and methods for the treatment of immune related diseases
    Patent number: 7381809
    Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: June 3, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Austin L. Gurney, Kenneth J. Hillan, Daniel Tumas, Colin K. Watanabe, William I. Wood
  • Anti-pro4407 antibodies
    Patent number: 7332578
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: February 19, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Anti-PRO4980 antibodies
    Patent number: 7312303
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: December 25, 2007
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Dan L. Eaton, Ellen Filvaroff, Audrey Goddard, J. Christopher Grimaldi, Austin L. Gurney, Victoria Smith, Jean Philippe Stephan, Colin K. Watanabe, William I. Wood, Zemin Zhang, Sherman Fong
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7304126
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: December 4, 2007
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Dan L. Eaton, Ellen Filvaroff, Audrey Goddard, J. Christopher Grimaldi, Austin L. Gurney, Victoria Smith, Jean Philippe Stephan, Colin K. Watanabe, William I. Wood, Zemin Zhang, Sherman Fong
  • PRO4407 polypeptides
    Patent number: 7304136
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: December 4, 2007
    Assignee: Genentech, inc.
    Inventors: Audrey Goddard, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Anti-PRO10268 antibodies
    Patent number: 7297333
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: November 20, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • PRO6496 polypeptides
    Patent number: 7297770
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods, for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: November 20, 2007
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Dan L. Eaton, Ellen Filvaroff, Audrey Goddard, J. Christopher Grimaldi, Austin L. Gurney, Victoria Smith, Jean Philippe Stephan, Colin K. Watanabe, William I. Wood, Zemin Zhang, Sherman Fong
  • PRO698 polypeptides
    Patent number: 7297769
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: November 20, 2007
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Dan L. Eaton, Ellen Filvaroff, Audrey Goddard, J. Christopher Grimaldi, Austin L. Gurney, Victoria Smith, Jean Philippe Stephan, Colin K. Watanabe, William I. Wood, Zemin Zhang, Sherman Fong
  • PRO7168 polypeptides
    Patent number: 7294696
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: November 13, 2007
    Assignee: Genentech Inc.
    Inventors: Kevin P. Baker, Dan L. Eaton, Ellen Filvaroff, Audrey Goddard, J. Christopher Grimaldi, Austin L. Gurney, Victoria Smith, Jean Philippe Stephan, Colin K. Watanabe, William I. Wood, Zemin Zhang, Sherman Fong
  • PRO10268 polypeptides
    Patent number: 7294695
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: November 13, 2007
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Dan L. Eaton, Ellen Filvaroff, Audrey Goddard, J. Christopher Grimaldi, Austin L. Gurney, Victoria Smith, Jean Philippe Stephan, Colin K. Watanabe, William I. Wood, Zemin Zhang, Sherman Fong